Inter- and intra-rater reliability for classification of medication related events in paediatric inpatients

Quality and Safety in Health Care

Volumn 15, Issue 3, 2006, Pages 196-201

  Kunac, D L ^a   Reith, D M ^b   Kennedy, J ^a   Austin, N C ^c   Williams, S M ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH WOMEN S HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; FLUCLOXACILLIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; ARTICLE; ASTHMA; CLASSIFICATION; CONTROLLED STUDY; HEALTH PRACTITIONER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL CARE; MEDICATION ERROR; PATIENT SAFETY; PEDIATRICS; PRESCRIPTION; PREVENTION STUDY; RASH; RELIABILITY; SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; CHILD; CHILD, PRESCHOOL; DECISION MAKING; HUMANS; INFANT; INFANT, NEWBORN; MEDICAL AUDIT; MEDICATION ERRORS; MEDICATION SYSTEMS, HOSPITAL; NEW ZEALAND; PEDIATRICS; SAFETY MANAGEMENT;

EID: 33745200247     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2005.014407     Document Type: Article

References (29)

1. Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals. Principal findings from a national survey. Occasional Paper No 3. Wellington: Ministry of Health. Available from http://www.moh.govt.nz/moh.nsf (accessed 9 February 2006).
2. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. JAMA 1995;274:29-34.
3. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.
4. Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004;13:306-14.
5. Brennan TA, Localio RJ, Laird NL. Reliability and validity of judgments concerning adverse events suffered by hospitalized patients. Med Care 1989;27:1148-58.
6. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
7. Dawson B, Trapp R. Basic and clinical biostatistics, 4th ed. New York: McGraw-Hill, 2004.
8. Dunn G. What is good agreement? In: Design and analysis of reliability studies: the statistical evaluation of measurement errors. New York: Oxford University Press, 1989:37-8.
9. Kaushal R. Using chart review to screen for medication errors and adverse drug events. Am J Health Syst Pharm 2002;59:2323-5.
10. ICH Steering Committee. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting. Available from http://www.ich.org (accessed 9 February 2006).
11. Schumock GT, Thornton JP. Focusing on the preventabilily of adverse drug reactions. Hosp Pharm 1992;27:538.
12. Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988;109:582-9.
13. Kozer E, Scolnik D, Macpherson A, et al. Variables associated with medication errors in pediatric emergency medicine. Pediatrics 2002;110:737-42.
14. King WJ, Paice N, Rangrej J, et al. The effect of computerized physician order entry on medication errors and adverse drug events in pediatric inpatients. Pediatrics 2003;112:506-9.
15. Potts AL, Barr FE, Gregory DF, et al. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics 2004;113:59-63.
16. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993;8:289-94.
17. Bales DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995;10:199-205.
18. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94.
19. Folli HL, Poole RL, Benitz WE, et al. Medication error prevention by clinical pharmacists in two children's hospitals. Pediatrics 1987;79:718-22.
20. Collier J. Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol 1999;48:5-8.
21. Conroy S. Unlicensed and off label drug use for paediatric patients. Optimal dosing schedules with gentamicin are needed for premature neonates. BMJ 1998;317:204-5.
22. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999;80:F142-4.
23. Conroy S, Choonara I, lmpicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320:79-82.
24. Turner S, Gill A, Nunn T, et al. Use of "off-label" and unlicensed drugs in paediatric intensive care unit, Lancet 1996;347:549-50.
25. Turner S, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998;316:343-5.
26. Goldman RL. The reliability of peer assessments of quality of care. JAMA 1992;267:958-60.
27. Easton-Carter KL, Chapman CB, Brien JE. Emergency department attendances associated with drug-related problems in paediatrics. J Paediatr Child Health 2003;39:124-9.
28. Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 2004;57:611-5.
29. Easton KL, Parsons BJ, Starr M, et al. The incidence of drug-related problems as a cause of hospital admissions in children. Med J Aust 1998;169:356-9.